Corsalex, Inc.

Corsalex’s mission is to identify, fund, and develop promising projects to treat C9orf72 ALS/FTD. Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are devastating adult-onset neurodegenerative diseases. Genetic analysis has revealed the hexanucleotide repeat expansion (HRE) disorder C9orf72 as the most common cause of familial ALS/FTD (C9-ALS/FTD). Corsalex is a joint venture between KCK and Panorama Research. Led by Dr. James Larrick, a biomedical entrepreneur with an international reputation and over 30-year career in biotechnology, and backed by KCK, the Company hopes to spur innovation and advance meaningful interventions for this devastating disease.